LCB from the beginning has outstanding research scientists who are well experienced in the field of drug research and development. The CEO, Yong-Zu Kim(Ph. D.), was a former director of New Drug Research Center at ‘LG Life Sciences’, which is one of the leading pharmaceutical companies in Korea. He had made excellent contributions to the pioneering field of new drug development with more than 23 years of experience. He had also faced with numerous setbacks but also triumphs in his walk. One of his remarkable achievements at LGLS was the invention of “FACTIVE(Quinolone antibiotics)”, which was the first US FDA approved drug, originated from Korea(launched in 2003). Moreover, he had been involved in a number of joint researches, co-developments and out-licensing deals with global pharmaceutical companies. Most of the key scientists including CTO, Tae Kyo, Park(Ph. D.), had their former careers at LGLS with CEO, then joined LCB as founding members in 2006. A dream and a passion for developing a global drug is a driving force to encourage us to work together for the future.

LCB has a powerful platform technology so-called ‘LegoChemistry’ as a method for medicinal chemistry. ‘LegoChemistry’ uses a unique scaffold with druglikeness which enables to discover drug candidates in a faster and more efficient way in combination with in vitro early ADME/T screening. LCB has more than twenty novel scaffolds. We have also set up our own guideline so-called “Gate Decision System”, which is a strict guideline for examining each step of drug-candidate discovery and its development process. Furthermore, conducting an open innovation program is our forte in terms of maximizing mutual benefits in cooperation with strategic alliance partners. Thus, We have the ability to enhance our drug research and development with global competitiveness.